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S280 Poster Session Iinfection. Procalcitonin (PCT) is a novel marker that reflects the se-
verity of infection. Allogeneic Hematopoietic Stem Cell Transplan-
tation (Allo-HSCT) patients often have febrile episodes, but it is not
easy to conclude that the fever is caused by infection. In this study, we
assessed the diagnostic usefulness of PCT for allo-HSCT patients
with fever.
Patients andMethods:We retrospectively analyzed among the 41
patients who underwent allo-HSCT at our hospital between Janu-
ary 2008 and July 2010, 17 patients with fever above 37.5C and
for whom PCT was measured (total of 28 febrile episodes). The
number of cases of underlying hematologic diseases were as fol-
lows: 11 acute myeloid leukemia, 2 myelodysplastic syndrome, 1
myeloproliferative disease, 6 acute lymphoid leukemia, 4 malignant
lymphoma, 2 aplastic anemia, 1 multiple myeloma, and 1 other dis-
ease. Fifteen and thirteen febrile events were from patients who
had myeloablative and non-myeloablative conditioning regimens,
respectively.
Results: We documented infection in 16/28 febrile episodes (13
bacterial infections, 2 fungal infections, and 1 viral infection), while
12 febrile episodes were not related to infection (10 acute GVHD, 1
drug, and 1 not specified). To determine whether the presence of
infection can be predicted by PCT, we divided the 41 patients
into two groups, one with neutrophil counts\ 100/ml (N\ 100
group) and the other with $ 100/ml (N $ 100 group). In the N
\ 100 group, the sensitivity, specificity, likelihood ratio, positive
predictive value, and negative predictive value were 42.8%, 75%,
1.7, 90.9%, and 27.2%, respectively; in the N $ 100 group, these
values were 50%, 75%, 2.0, 33.3%, and 85.7%, respectively. Dur-
ing neutropenia, positive PCT tended to show the presence of in-
fection. However, when the neutrophil count gradually increased,
fever with positive PCT tended to have non-infectious factors,
such as allograft immunoreactions. These results suggest that the
cause of fever could not be predicted by PCT alone when the neu-
trophils reach a certain level. However, the probability of a false
negative prediction of infection by PCT tended to decrease with
the increase of neutrophil count. Further analysis will be needed
with inflammatory markers and clinical signs together with PCT
in a prospective study to determine the utilization of PCT for
allo-HSCT patients.348
CARING FOR THE CAREGIVER IN THE STEM CELL TRANSPLANTATION
SETTING
Brown, S.L. The University of Texas M.D. Anderson Cancer Center,
Houston, TX
Caring for a sick person, especially one with cancer can be
a long term, overwhelming responsibility. Caring for these patients
often requires support across the continuum, to address physical,
psychosocial, spiritual, and emotional well-being. Expectations in-
clude, managing an increasingly complicated healthcare system, re-
maining optimistic, and taking care of personal needs, usually
without support for themselves. This is especially true in stem
cell transplantation settings where patient hospitalizations can
last for several weeks and daily outpatient clinic visits for several
months. Unaddressed caregiver needs present risks to physical
and mental health, which in turn may affect the care provided
for loved ones.
To address this concern, Caregiver’s Week was implemented on
a stem cell transplantation unit. This event was designed to address
caregiver stress by using techniques such as relaxation, diversion,
support, meeting spiritual needs, and providing an opportunity to re-
spond to concerns and questions of caregivers. Program components
include Bingo, Tea/TLC, crafts, relaxation, and holiday themed
events. Nursing staff is present to address questions, concerns, and
listen to caregivers discuss their experiences. A chaplain is available
to provide spiritual support as appropriate. This collaborative ap-
proach allows caregivers to receive support, as well as support one
another.
The response to Caregiver’s Week is overwhelmingly positive.
Participants report feeling rejuvenated, relaxed, and in better spirits.
In addition, they report making friends who are going through the
same experience and whom they feel understand their feelings;many of these friendships continue long-term, after patients are dis-
charged.
Supporting caregivers is essential in stem cell transplantation to
decrease stress, increase morale, and create support. By providing
a week of activities focused on caregivers, staff acknowledges the es-
sential role they play in promoting positive patient care and out-
comes. Future plans include continuation of the Caregiver Week
activities, incorporating additional supportive measures, as well as
creating new innovative events, while continuing to monitor prog-
ress and meet caregiver needs.349
SUPPORTING BONE MARROW TRANSPLANT CAREGIVERS: NURSING’S
INFLUENCE ON INCORPORATING CAREGIVER SUPPORT SERVICES INTO
THE DESIGN OF A NEW BONE MARROW TRANSPLANT UNIT
Spruill, A.D., Eron, B.W. University of North Carolina Healthcare,
Chapel Hill, NC
During the planning stages of the new North Carolina Cancer
Hospital (NCCH), nursing was solicited for their design input.
The BoneMarrowTransplant Unit (BMTU) staff nurses at theUni-
versity of North Carolina Healthcare recognized the opportunity to
address some stressors that transplant caregivers may face. Nursing
staff used this opportunity to incorporate caregiver support services
into the design of the new, larger facility. In an effort to decrease
transplant caregiver burden, several amenities for caregivers were
created.
In response to caregiver needs, a caregiver suite was created on
the unit. Within this area, a laundry room with a full sized washer
and dryer was incorporated. Also located within this area are two
separate sleep rooms. Each of these rooms contain two beds as
well as a television, sofa, and radio for patients’ caregivers; allow-
ing them to rest outside of the patient’s room without having to
leave the hospital. A shower facility is also located within this
same area.
A nourishment room was designed for caregivers’ convenience.
This room contains a full sized refrigerator, microwave, coffee ma-
chine, and cabinet space assigned to them for storage. Additionally,
the Comprehensive Cancer Support Program within the NCCH of-
fers caregivers breakfast every Friday morning as well as Tuesday
night dinner.
The unit’s waiting room functions as a meeting space for care-
givers. There is a computer, printer, and a microwave for their use.
This area hosts a weekly caregiver support group session lead by
the BMTU social worker and recreational therapist. A bulletin board
is also posted in this area to keep transplant caregivers abreast of sup-
port services available to them.
Nursing was highly influential in the implementation of these sup-
port amenities that has served to address and decrease some of the
daily stressors that some transplant caregivers experience.350
THE EFFECT OF DONOR CYTOMEGALOVIRUS (CMV) SEROLOGIC STATUS
ON OUTCOME AND SURVIVAL IN PATIENTS UNDERGOING ALLOGENIC
STEM CELL TRANSPLANTATION IN THE ERA OF CMV-PREEMPTIVE THER-
APY
Koh, L.P.1, Tay, P.F.1, Poon, M.L.M.1, Hwang, W.Y.K.2, Loh, Y.S.M.2,
Tan, L.K.1, Goh, Y.T.2, Tan, B.1, Lee, J.J.2, Zhang, X.H.2, Lee, Y.M.1,
Ng, H.Y.1, Linn, Y.C.1 1National University Health System, Singapore;
2Singapore General Hospital, Singapore
Background: Cytomegalovirus continues to be a common cause of
morbidity and mortality after allogenic hematopoietic stem cell
transplantation (SCT) despite major advances in diagnostic tech-
niques and antiviral prophylactic strategies. Recipient CMV-sero-
positivity is a major predictor of adverse outcomes. Data regarding
the effect of the donor serologic status on seropositive recipient out-
comes remains controversial, with some studies reporting a beneficial
effect of seropositive donor, either reduction in relapse or reduction
in nonrelapse mortality (NRM), whereas other studies have found no
benefit from seropositive donor.
Poster Session I S281Methods: We reviewed the records of CMV-seropositive patients
who underwent allogenic SCT in two tertiary institutions in Singa-
pore between 2006 and 2010. The studied outcomes included CMV
reactivation, CMV disease, and 100-day mortality.
Results: 179 CMV-seropositive patients (median age 43) who un-
derwent myeloablative (N 5 78) and nonmyeloablative (N 5 101),
related (N 5 122) and unrelated (N 5 57) donor allogenic SCT
were identified. Among them, 145 (81%) had a CMV-seropositive
donor, and 34 (19%) had a CMV-seronegative donor. Median fol-
low-up time was 8.2 months. There were no significant differences
in the studied outcomes. CMV reactivation occurred in 93 (64%) pa-
tients in the CMV-seropositive donor group, and 23 (68 %) patients
in the CMV-negative donor group. CMV disease occurred in 4 (3%)
patients in the CMV-seropositive donor group and 2 (6%) in the
CMV-seronegative donor group. The 100-day mortality was 11%
in both the CMV-seronegative and CMV-seropositive donor group.
There was no statistically significant difference in 3 year disease free
survival between the two groups. A secondary aim of establishing risk
factors for CMV reactivation was performed. In multivariate analy-
sis, the use of thymoglobuline prophylaxis was observed to be the
only significant predictors for CMV reactivation. Patients receiving
thymoglobuline prophylaxis were observed to be 3.6 times more
likely to experience CMV reactivation, as compared to those who
did not receive it.
Conclusions:Our study shows that donor CMV serologic status did
not significantly affect the incidence of CMV reactivation, CMVdis-
ease, 100- day mortality, and disease free survival in CMV-seropos-
itive patients undergoing allogenic SCT. The use of thymoglobuline
prophylaxis, however, remains the most important risk factors for
CMV reactivation.351
INVASIVE FUNGAL INFECTIONS IN PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANT PATIENTS, A RETROSPECTIVE ANALYSIS
Rosenthal, J.1, Ito, J.2, Tegtmeier, B.2,Wolfson, J.1, April, S.1, Cheng, J.3,
Pawlowska, A.1 1City of Hope, Duarte, CA; 2City of Hope, Duarte, CA;
3Kaiser-Permanente, Los Angeles, CA
Background: Invasive fungal infections (IFI) remain a major cause
of morbidity and mortality in patients (pts) undergoing HCT. The
epidemiology of IFI has changed, with a higher proportion of mould
infections reported compared to earlier reports (Marr et al. Clin In-
fect Dis. 2002). The incidence of IFI in children undergoing HCT
has been reported at a range of 1.6-25%. The changes in epidemiol-
ogy of IFI are attributed to multiple factors, including corticosteroid
treatment, graft-versus-host disease (GVHD), increase in trans-
plants from alternative donors, and emergence of resistance with
use of azoles for IFI prevention. We report a low incidence of IFI
in pediatric patients treated in an arid region, using low-dose ampho-
tericin prophylaxis.
Methods:Medical records of 49 of 501 pediatric pts who had under-
gone 550 HCT procedures at our center between January 1997 and
August 2010 have been reviewed. Categorical tables were analyzed
using Pearson’s chi-square test and the Cochran-Mantel-Haenszel
test. Tabular and graphical descriptive survival analyses were per-
formed using cumulative incidence methods accounting for compet-
ing risks.
Results: Probable or proven IFI were diagnosed in 49 pts; 44 were
diagnosed within 2 years of HCT and were considered to be related
to treatment. The median age was 12.8 years (range 1-19.6 years).
Amphotericin based prophylaxis was used in 39 pts (87%) and other
agents in 5 pts (13%). Yeast and mould infections were diagnosed in
17 (2.7%) and 29 (5.2%) patients respectively. Two patients had
both yeast and mould infections. Yeast infection was bi-phasic, the
first peak (n 5 11) occurring at a median of 56 days (2-360) and
the second (n 5 6) at 400 days (365-478), post HCT, respectively.
The median day for mould infection was day +142 (10-726). HCT
modality, GVHD, steroid use, co-infection with viral or bacterial in-
fection and previous HCT were associated with IFI. The immediate
outcome of the event was resolution (n5 16, 37%), death from fun-
gal infection (n 5 12, 28%) death of disease progression (n 5 8,19%), GVHD (n 5 4, 8%) and death from other transplant related
complications (n 5 4, 8%),
Conclusion: The risk of IFI reported here appears to be lower than
historical data. This may be related to the vast use of low-dose am-
photericin formulations for prophylaxis, the arid climate, or a combi-
nation of both. A prospective study is needed to further elucidate the
role of low-dose amphotericin in prevention of IFI in HCT pts.352
INCIDENCE OF HYPERGLYCEMIA IN ACUTE ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT
Schlatter, M., Gregory, T.K., Panter, E., Maris, M.B., McSweeney, P.
Colorado Blood Cancer Institute, Denver, CO
Introduction: Medical literature has established adverse clinical
outcomeswith hyperglycemia and adverse events in the inpatient set-
ting. There is a paucity of literature documenting the incidence and
subsequent effects of hyperglycemia in HSCT patients. The data in
other populations shows decreased rates of infection, morbidity and
mortality with improved glycemic control. This suggests that im-
proved glycemic control in the HSCT setting could reduce rates
of infection, GvHD, and TRM. The goal of this study is to describe
the incidence of hyperglycemia in the allo HSCT population.
Patients and Methods: A chart review was conducted on a total of
167 HCST patients up to day +100. Thirty normoglycemic, auto
HSCT recipients served as controls. The remaining 137 were allo
HSCT recipients. The primary endpoint was the incidence of hyper-
glycemia defined as one random blood glucose (BG) . 180 mg/dL.
Severe hyperglycemia was defined as BG . 250 mg/dL. Secondary
endpoints included administration of steroids, insulin, and death.
Results were analyzed utilizing Pearson’s chi squared test.
Results: Sixty patients had at least one BG from 180-250mg/dL and
68 had a BG . 250 mg/dL. The overall incidence of hyperglycemia
(. 180 mg/dL) was 76% in the study group compared to zero inci-
dence in the control group (p0.007). The majority of patients with
hyperglycemia received insulin therapy (95%). Probability of day
+100 survival was 72% if BG . 250 mg/dL, 84% for level of 180-
250 mg/dL, and 96% with levels\ 180 mg/dL. The survival rate
in the allo study group for BG\ 180 mg/dL was 96% compared
to 77% for a BG . 180 (p0.008).
Conclusions:While there is a clear increased incidence of hypergly-
cemia in the allo HSCT population, it remains unclear if this is caus-
ally related to adverse outcomes. Many factors impact survival
probability and the relationship of aggressive glucose control and
improved outcomes have yet to be examined. Further study of hyper-
glycemia, confounding variables, and aggressive insulin therapy in
a randomized, prospective manner is needed.353
INHALED AEROSOLIZED RIBAVIRIN TREATMENT IN RAPID ANTIGEN
TEST NEGATIVE AND MULTIPLEX PCR POSITIVE RESPIRATORY SYNCY-
TIAL VIRAL PNEUMONIA AFTER STEM CELL TRANSPLANTATION: A SIN-
GLE CENTER EXPERIENCE OVER TWO WINTER SEASONS
Ganguly, S.1, Ganguly, N.2, Carson, S.3, Aljitawi, O.1, Abhyankar, S.1,
McGuirk, J.P.1 1University of Kansas Medical Center, Kansas City, KS;
2University of Kansas Medical Center, Kansas City, KS; 3University of
Kansas Medical Center, Kansas City, KS
Respiratory Syncytial Virus (RSV) pneumonia leading to respira-
tory failure can be a significant cause of acute morbidity and mortal-
ity in the immuno-compromised host, with mortality rates of 70 to
100 percent being described in bone marrow transplant recipients.
High level of suspicion, availability ofmultiplex polymerase chain re-
action (PCR) technique for early detection, and immediate interven-
tion by inhaled Ribavirin may lead to improved outcome.
As a policy of our program, nasal wash samples from the transplant
recipients with respiratory symptoms are routinely sent for both
rapid antigen detection tests as well as for multiplex respiratory viral
panel PCR. We identified a total of 6 patients with RSV pneumonia
